Clinical Trials Logo

Rhabdomyosarcoma clinical trials

View clinical trials related to Rhabdomyosarcoma.

Filter by:

NCT ID: NCT01532687 Completed - Sarcoma Clinical Trials

Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma

Start date: March 13, 2012
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well gemcitabine hydrochloride works with or without pazopanib hydrochloride in treating patients with refractory soft tissue sarcoma. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether gemcitabine hydrochloride is more effective with or without pazopanib hydrochloride in treating patients with soft tissue sarcoma.

NCT ID: NCT01524926 Completed - Clinical trials for Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma

CREATE: Cross-tumoral Phase 2 With Crizotinib

CREATE
Start date: September 2012
Phase: Phase 2
Study type: Interventional

The study will primarily assess the antitumor activity of crizotinib in a variety of tumors with alterations in ALK and/or MET pathways. The targeted patient population will include patients with tumors harboring specific alterations leading to ALK and/or MET activation, where tyrosine kinase inhibitors against these targets have not yet been adequately explored.

NCT ID: NCT01518413 Completed - Neuroblastoma Clinical Trials

Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors

Start date: December 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safest and most effective oral dose combinations of sorafenib and irinotecan in pediatric patients with solid tumors, i.e. relapsed or refractory.

NCT ID: NCT01505569 Completed - Soft Tissue Sarcoma Clinical Trials

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Start date: October 20, 2011
Phase: N/A
Study type: Interventional

This is a standard of care treatment guideline for high risk or relapsed solid tumors or CNS tumors consisting of a busulfan, melphalan, thiotepa conditioning (for solid tumors) or carboplatin and thiotepa conditioning (for CNS tumors) followed by an autologous peripheral blood stem cell transplant. For solid tumors, if appropriate, disease specific radiation therapy at day +60. For CNS tumors, the conditioning regimen and autologous peripheral blood stem cell transplant will be given for 3 cycles.

NCT ID: NCT01502410 Completed - Clinical trials for Papillary Thyroid Cancer

Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

Start date: January 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well sorafenib tosylate works in treating younger patients with relapsed or refractory rhabdomyosarcoma, Wilms tumor, liver cancer, or thyroid cancer. Sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01496573 Completed - Clinical trials for Embryonal Childhood Rhabdomyosarcoma

Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma

Start date: December 2011
Phase: N/A
Study type: Observational

This research trial studies biomarkers in tumor tissue samples from younger patients with rhabdomyosarcoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer

NCT ID: NCT01466283 Completed - Sarcoma Clinical Trials

Biomarkers in Patients With Rhabdomyosarcoma

Start date: October 2011
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in patients with rhabdomyosarcoma.

NCT ID: NCT01433237 Completed - Sarcoma Clinical Trials

Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma

Start date: September 2011
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies biomarkers in samples from patients with rhabdomyosarcoma.

NCT ID: NCT01426945 Completed - Sarcoma Clinical Trials

Protein Expression in Samples From Young Patients With Rhabdomyosarcoma

Start date: November 2011
Phase: N/A
Study type: Observational

RATIONALE: Studying tissue samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer. PURPOSE: This research trial studies protein expression in samples from young patients with rhabdomyosarcoma.

NCT ID: NCT01419509 Active, not recruiting - Sarcoma Clinical Trials

DNA Tests in Detecting Disseminated Disease in Tumor, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma

Start date: August 2011
Phase: N/A
Study type: Observational

RATIONALE: DNA analysis of tumor, blood, and bone marrow may help doctors predict if the disease has been disseminated. PURPOSE: This research trial studies DNA tests in detecting disseminated disease in tumor, blood, and bone marrow samples from patients with rhabdomyosarcoma.